Suma Krishnan, who serves as a director and as President, R&D at Krystal Biotech, Inc. (NASDAQ: KRYS), sold a total of 23,799 shares of the company's common stock on March 4, 2026. The share disposals were completed across multiple trades, with transaction prices spanning from $257.3186 to $266.4224 and producing aggregate proceeds of approximately $6.58 million.
The most detailed reported lot shows Krishnan sold 407 shares at $257.3186, equating to $104,728. The remaining sales were executed in several blocks and price ranges: 589 shares (between $257.93 and $258.92); 668 shares (between $258.98 and $259.97); 3,667 shares (between $259.98 and $260.97); 2,931 shares (between $261 and $261.99); 1,938 shares (between $262 and $262.8); 2,248 shares (between $263 and $263.99); 4,852 shares (between $264 and $264.97); 6,000 shares (between $265 and $265.73); and 1,700 shares (between $266 and $266.93).
Following these transactions, Krishnan retains direct ownership of 1,403,155 shares of Krystal Biotech common stock. In addition to direct holdings, Krishnan has indirect ownership of 90,000 shares through the SMK Trust and 50,000 shares through the Krishnan Family Trust.
The sales were made pursuant to a Rule 10b5-1 trading arrangement that Krishnan adopted on September 4, 2025. That plan began executing trades on December 4, 2025, and is scheduled to terminate on December 4, 2026.
In separate company news, Krystal Biotech released fourth-quarter 2025 financials showing results ahead of analysts' expectations. The company reported earnings per share of $1.70, topping the forecast of $1.58. Revenue for the quarter totaled $107.1 million, surpassing the consensus estimate of $106.16 million. The company noted that these figures were stronger than anticipated, drawing attention from market participants.
While market reaction and specific share-price movements following the financial release were observed, those fluctuations are not the focus here. Investors and analysts remain attentive to Krystal Biotech's operational and financial trajectory in light of the stronger-than-expected quarterly results and the insider sale conducted under the preexisting trading plan.
Context and notes: All transaction details, ownership figures, trading-plan dates, and the reported fourth-quarter financial results are taken from company disclosures. No additional events, dates, or numerical information have been added.